AtriAN uses a gentle energy, micro Pulsed Electric Fields (mPEF) to only ablate neuronal cells. The other tissues such as the myocardium are spared.


Most ablation techniques use either heat (burning) or cold (freezing) to ablate tissue with an intent to create scar tissue which damage surrounding healthy tissues. Our PEF is non-thermal.


Our unique approach of targeting neuronal cells in the clusters known as ganglionated plexi (GPs) should prove from first principle to have a permanent effect.

Mission & Vision

Resolving Atrial Fibrillation at its Origin

Current therapies are failing many patients. These approaches only isolate errant signals which still remain present and this isolation often fails over time. AtriAN targets and permanently disables them.


A Disruptive Approach to Rhythm restoration

AtriAN brings two significant approaches to the long-term resolution of Atrial Fibrillation. We navigate to the epicardial (outside) surface of the heart AND we target ganglionated plexi (GPs) –hyperactive cells structures, with a new and sparing energy.


AtriAN’s Business Pathway

Growing Market

Atrial Fibrillation is a huge, and quickly growing market that problem that is underserved. There exists no perfect solution yet for its resolution.

Robust and Innovative Intellectual Property (IP)

The idea and technology were conceived and first developed at the Mayo Clinic (Rochester, MN, USA) by Dr. Sam Asirvatham with issued patents across the globe. We continue to innovate the technology.

Unique Solution

Atrian takes a novel and unique approach to the resolution of the disease by targeting and disabling the hyperactive signals responsible for the arrhythmia.

Funding in Place

AtriAN has raised over €5M in funding bringing us to that exciting stage of first clinical treatments. We are seeking expressions of interest from investors for the next stage of our journey.

Unmet Need

Existing medications have a very high failure rate and affect every organ in the body. Current ablation technologies only seek to block the signals responsible for this condition; this results in recurrence rates that are far too high.

First In Human (FIH) Trials

AtriAN is excited to announce that we have started our First-In-Human (FIH) Trial to demonstrate our technology in patients.

R & D

Research & Development

In addition to our work with Gentle Pulsed Fields (electroporation) that spare the heart’s delicate tissues, we are progressing our R&D with innovative, unique and minimally-invasive catheters to reach the origin of the condition on the epicardial surface of the heart.

gentle Pulsed Fields

Our team has been involved with the development of Pulsed Fields (electroporation) for many years. Our pre-clinical data has shown this energy is sparing to the heart muscle.

Autonomics Remodeling

Neuromodulation has been one of the most exciting and disruptive approaches to medicine in recent years. Our approach is to restore the autonomic tone of the heart by targeting and disabling the ganglionated plexi (GP) structures.

Sub-Xiphoid Approach

We are using a unique and minimally-invasive Sub-Xiphoid approach with our unique and patented catheters.


Resources & News

Get Started

Work with Us

If you have an interest in helping AtriAN bring this revolutionary and disruptive treatment to patients world-wide, please contact us.